These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 17567883)

  • 41. Cognitive function during 3 years of growth hormone in previously growth hormone-treated young adults with Prader-Willi syndrome.
    Trueba-Timmermans DJ; Grootjen LN; Juriaans AF; Mahabier EF; Kerkhof GF; Rings EHHM; Hokken-Koelega ACS
    Eur J Endocrinol; 2023 Jul; 189(1):132-139. PubMed ID: 37440711
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Growth hormone therapy in young children with Down syndrome and a clinical comparison of Down and Prader-Willi syndromes.
    Annerén G; Tuvemo T; Gustafsson J
    Growth Horm IGF Res; 2000 Apr; 10 Suppl B():S87-91. PubMed ID: 10984260
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of growth hormone treatment on growth and body composition in Prader-Willi syndrome: a preliminary report. The Swedish National Growth Hormone Advisory Group.
    Lindgren AC; Hagenäs L; Müller J; Blichfeldt S; Rosenborg M; Brismar T; Ritzén EM
    Acta Paediatr Suppl; 1997 Nov; 423():60-2. PubMed ID: 9401542
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bone mineral density and effects of growth hormone treatment in prepubertal children with Prader-Willi syndrome: a randomized controlled trial.
    de Lind van Wijngaarden RF; Festen DA; Otten BJ; van Mil EG; Rotteveel J; Odink RJ; van Leeuwen M; Haring DA; Bocca G; Mieke Houdijk EC; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3763-71. PubMed ID: 19622627
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Two years of growth hormone therapy in young children with Prader-Willi syndrome: physical and neurodevelopmental benefits.
    Myers SE; Whitman BY; Carrel AL; Moerchen V; Bekx MT; Allen DB
    Am J Med Genet A; 2007 Mar; 143A(5):443-8. PubMed ID: 17103437
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The efficacy and safety of long-term Norditropin® treatment in children with Prader-Willi syndrome.
    Meinhardt U; Christiansen JS; Farholt S; Lämmer C; Ostergaard JR; Schmidt F; Kappelgaard AM; Eiholzer U
    Horm Metab Res; 2013 Jul; 45(7):532-6. PubMed ID: 23632904
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The GHRH + arginine stimulated pituitary GH secretion in children and adults with Prader-Willi syndrome shows age- and BMI-dependent and genotype-related differences.
    Marostica E; Grugni G; De Nicolao G; Marazzi N; Crinò A; Cappa M; Sartorio A
    Growth Horm IGF Res; 2013 Dec; 23(6):261-6. PubMed ID: 24090687
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A polymorphism in the growth hormone receptor is associated with height in children with Prader-Willi syndrome.
    Park SW; Lee ST; Sohn YB; Kim SH; Cho SY; Ko AR; Ji ST; Kwon JY; Yeau S; Paik KH; Kim JW; Jin DK
    Am J Med Genet A; 2011 Dec; 155A(12):2970-3. PubMed ID: 22052808
    [TBL] [Abstract][Full Text] [Related]  

  • 49. IGF-1 Levels, Complex Formation, and IGF Bioactivity in Growth Hormone-Treated Children With Prader-Willi Syndrome.
    Bakker NE; van Doorn J; Renes JS; Donker GH; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2015 Aug; 100(8):3041-9. PubMed ID: 26050733
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adult height after long-term, continuous growth hormone (GH) treatment in short children born small for gestational age: results of a randomized, double-blind, dose-response GH trial.
    Van Pareren Y; Mulder P; Houdijk M; Jansen M; Reeser M; Hokken-Koelega A
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3584-90. PubMed ID: 12915640
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Body composition abnormalities in children with Prader-Willi syndrome and long-term effects of growth hormone therapy.
    Eiholzer U; l'Allemand D; van der Sluis I; Steinert H; Gasser T; Ellis K
    Horm Res; 2000; 53(4):200-6. PubMed ID: 11044804
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Growth hormone treatment of children with Prader-Willi syndrome: effects on glucose and insulin homeostasis. Swedish National Growth Hormone Advisory Group.
    Lindgren AC; Hagenäs L; Ritzén EM
    Horm Res; 1999; 51(4):157-61. PubMed ID: 10474015
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical Characteristics and Growth Hormone Treatment in Patients with Prader-Willi Syndrome.
    Dağdeviren Çakır A; Baş F; Akın O; Şıklar Z; Özcabı B; Berberoğlu M; Kardelen AD; Bayramoğlu E; Poyrazoğlu Ş; Aydın M; Törel Ergür A; Gökşen D; Bolu S; Aycan Z; Tüysüz B; Ercan O; Evliyaoğlu O
    J Clin Res Pediatr Endocrinol; 2021 Aug; 13(3):308-319. PubMed ID: 33565750
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Visceral adipose tissue resides within the reference range in children with Prader-Willi syndrome receiving nutritional intervention on a regular basis.
    Koizumi M; Ida S; Shoji Y; Nishimoto Y; Etani Y; Kawai M
    Endocr J; 2020 Oct; 67(10):1029-1037. PubMed ID: 32565499
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Endocrine and metabolic aspects of adult Prader-Willi syndrome with special emphasis on the effect of growth hormone treatment.
    Höybye C
    Growth Horm IGF Res; 2004 Feb; 14(1):1-15. PubMed ID: 14700552
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Physical effects of growth hormone treatment in children with Prader-Willi syndrome.
    Myers SE; Carrel AL; Whitman BY; Allen DB
    Acta Paediatr Suppl; 1999 Dec; 88(433):112-4. PubMed ID: 10626559
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Time for a general approval of growth hormone treatment in adults with Prader-Willi syndrome.
    Höybye C; Holland AJ; Driscoll DJ;
    Orphanet J Rare Dis; 2021 Feb; 16(1):69. PubMed ID: 33557878
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prader-Labhart-Willi syndrome: auxological response to a conventional dose of growth hormone in patients with classical growth hormone deficiency.
    Schmidt H; Bechtold S; Schwarz HP
    Eur J Med Res; 2000 Jul; 5(7):307-10. PubMed ID: 10903191
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome.
    Myers SE; Carrel AL; Whitman BY; Allen DB
    J Pediatr; 2000 Jul; 137(1):42-9. PubMed ID: 10891820
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serum adiponectin levels in adults with Prader-Willi syndrome are independent of anthropometrical parameters and do not change with GH treatment.
    Hoybye C; Bruun JM; Richelsen B; Flyvbjerg A; Frystyk J
    Eur J Endocrinol; 2004 Oct; 151(4):457-61. PubMed ID: 15476445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.